Latest News
- ARCHIVIERT
Wednesday - October 5, 2016
Bayer completes sale of Bayer Garden and Bayer Advanced businesses to SBM » more
- ARCHIVIERT
Tuesday - October 4, 2016
Not intended for U.S. and UK Media
Bayer receives green light for new five-year contraceptive in the EU
New low dose levonorgestrel-releasing intrauterine system will be named “Kyleena™” / Introduction in Europe is scheduled to start in January 2017 » more
- ARCHIVIERT
Thursday - September 29, 2016
Not intended for U.S. and UK Media
Bayer comments on article in The British Medical Journal (BMJ) regarding Xarelto® » more
- ARCHIVIERT
Wednesday - September 28, 2016
Not intended for U.S. and UK Media
Pivotal Phase III Study Started With Vericiguat in Patients With Chronic Heart Failure » more
- ARCHIVIERT
Tuesday - September 20, 2016
“Meet Management” investor conference:
Bayer sets ambitious growth and earnings aspirations
Further sales and earnings growth pursued in all businesses / Combined peak annual sales potential of recently launched pharmaceutical products raised to over EUR 10 billion / Six further product candidates in the Pharmaceuticals pipeline have combined peak sales potential of at least EUR 6 billion / Strong brands driving business at Consumer Health / Above-market sales growth and substantial margin increases expected at Crop Science following the closing of the agreed acquisition of Monsanto » more
- ARCHIVIERT
Monday - September 19, 2016
Not intended for U.S. and UK Media
FDA approves new five-year-contraceptive of Bayer » more
- ARCHIVIERT
Tuesday - September 6, 2016
Negotiations regarding Monsanto acquisition advance » more
- ARCHIVIERT
Monday - August 29, 2016
Not intended for U.S. and UK Media - ESC Congress 2016:
Real-World Data from Multiple Countries Continue to Reaffirm Positive Benefit-Risk Profile of Bayer’s Xarelto® in Everyday Clinical Practice
Late-breaking XAPASS study in patients with non-valvular atrial fibrillation (AF) in Japan reaffirms low rates of both stroke and major bleeding with Xarelto in routine clinical practice, consistent with Phase III J-ROCKET AF / Ongoing post-authorisation safety study based on Registers in Sweden confirms low rates of intracranial bleeding with Xarelto vs. warfarin in line with ROCKET AF / Additional real-world data presented from REVISIT-US study, which investigated rivaroxaban, apixaban and dabigatran, each compared with warfarin, in patients with non-valvular AF / Real-world data on Xarelto provide additional insights beyond Phase III clinical trials and better represent the diverse patient populations treated in routine clinical practice » more
- ARCHIVIERT
Monday - August 22, 2016
Not intended for U.S. and UK Media
New Real-World Evidence on Venous and Arterial Blood Clot Management including Bayer’s Xarelto® Accepted for Presentation at ESC Congress 2016
New real-world data will provide further insights on the use of Xarelto across diverse patient populations seen in everyday clinical practice / Results from the real-world observational XAPASS study of Xarelto in everyday patients with non-valvular AF in Japan will be presented during a Late-Breaking Registries Session / New real-world data from REVISIT-US investigating rivaroxaban, apixaban and dabigatran, each compared with warfarin, in patients with non-valvular AF will be presented during a Poster Session » more
- ARCHIVIERT
Tuesday - July 19, 2016
Bayer Comments on Monsanto’s Statement Regarding its Increased All-cash Offer » more
- ARCHIVIERT
Tuesday - June 28, 2016
Not intended for U.S. and UK Media: Phase III data at ESMO 18th World Congress on Gastrointestinal Cancer (WCGC):
Bayer’s Regorafenib Significantly Improves Overall Survival in Patients with Unresectable Liver Cancer
Initial results from Phase III trial RESORCE to be presented as Late-Breaking Abstract in oral abstract session at WCGC / Median overall survival was 10.6 months for patients treated with regorafenib plus best supportive care versus 7.8 months in the group treated with placebo plus best supportive care » more
- ARCHIVIERT
Friday - June 3, 2016
Not intended for U.S. and UK Media
Bayer and Orion Expand Clinical Development Program With New Phase III Study ARASENS for BAY-1841788 (ODM-201) in Prostate Cancer
Phase III study ARASENS to be initiated in metastatic hormone sensitive prostate cancer assessing the novel androgen-receptor antagonist in combination with standard androgen deprivation therapy and the chemotherapy docetaxel / Start of patient enrolment expected towards the end of 2016 » more
- ARCHIVIERT
Wednesday - June 1, 2016
Not intended for U.S. and UK Media - New Phase III Study for Stivarga® (Regorafenib):
Bayer collaborates with U.S. National Surgical Adjuvant Breast and Bowel Project (NSABP) to Investigate Stivarga® (Regorafenib) as Additional Adjuvant Therapy in Colon Cancer
Study will include patients with Stage IIIB and IIIC colon cancer who have undergone complete surgical resection of primary tumor and received standard adjuvant chemotherapy / Indication-seeking trial will be conducted by NSABP with the support from Bayer » more
- ARCHIVIERT
Tuesday - May 24, 2016
Bayer Comments on Monsanto’s Statement Regarding Proposed Transaction » more
- ARCHIVIERT
Thursday - May 19, 2016
Bayer Confirms Preliminary Discussion Regarding Acquisition of Monsanto » more
- ARCHIVIERT
Thursday - May 12, 2016
Not intended for U.S. and UK Media
Bayer Terminates Phase II Study with Riociguat in Patients with Pulmonary Hypertension Associated with Idiopathic Interstitial Pneumonias » more
- ARCHIVIERT
Wednesday - May 4, 2016
Not intended for U.S. and UK Media
Phase III Trial of Regorafenib in Patients with Unresectable Liver Cancer Meets Primary Endpoint of Improving Overall Survival » more
- ARCHIVIERT
Monday - April 25, 2016
Not intended for U.S. and UK Media
Patent Term for Rivaroxaban Extended in US » more
- ARCHIVIERT
Thursday - April 21, 2016
Bayer deposits 10 million Covestro shares in Bayer Pension Trust e. V. » more
- ARCHIVIERT
Monday - April 18, 2016
Not intended for U.S. and UK Media - 12th Annual Congress of the European Cardiac Arrhythmia Society (ECAS) 2016:
New Data Reaffirm Positive Benefit-Risk Balance of Bayer’s Xarelto® in Patients with Atrial Fibrillation in Daily Clinical Practice
Insights from nearly 23,000 patients with atrial fibrillation on the prevention of stroke and incidence of intracranial haemorrhage with Xarelto vs. warfarin / Results confirm the efficacy and safety profile of Xarelto as determined in pivotal Phase III ROCKET AF and other real-world studies » more
Copyright @ Bayer AG
Search
Publications
Newsletter
Events
Tuesday, November 9, 2021
Q3 2021 Quarterly Statement
Additional Press Events
Investor Relations Events
BayKomm Events
Download Center - Selection
Bayer TV